Aims-To examine human papillomavirus (HPV) positive and negative squamous cell carcinomas of the cervix for structural alterations in exon 1 c-myc; and to investigate the expression pattern of p62, the protein product of c-myc. Material-Archival paraffin wax embedded tissues of cervical squamous cell carcinomas, stage I and II, retrieved from the files of the department of pathology, University College Cork, Ireland: 40 cases were examined for alterations in exon 1 of c-myc; 57 cases were used for immunocytochemical p62 analysis. Methods-c-myc exon 1 PCR on HPV positive and negative stage I and II cervical squamous cell carcinomas was performed using primers designed to fragile sites in exon 1 of the c-myc oncogene, which are frequently involved in translocation phenomena and deletions in other neoplasms. This region is bordered by two promoter sequences PI and P2. In addition, the expression of p62 was evaluated using the monoclonal antibody Mycl-9E10.
cervical squamous cell carcinomas was performed using primers designed to fragile sites in exon 1 of the c-myc oncogene, which are frequently involved in translocation phenomena and deletions in other neoplasms. This region is bordered by two promoter sequences PI and P2. In addition, the expression of p62 was evaluated using the monoclonal antibody Mycl-9E10.
Results-Alterations in exon 1 of c-myc were shown in 7.5% of squamous cell carcinomas of the cervix. Changes in exon 1 and 2 of c-myc were also found in COLO 320 cells and Raji cells. These alterations were due to small deletions within exon 1 ofc-myc, but point polymorphisms occurring within the priming sites (in one case) may also have occurred. The alterations uncovered appeared "clonal," as replicate samples showed the same amplicon band pattern. Expression of c-myc was variable, with cytoplasmic staining patterns predominating. All cases which showed exon 1 alterations were HPV positive and had strong nuclear positivity on p62 immunocytochemistry.
Conclusions-Alterations in exon The c-myc oncogene is expressed in almost all differentiated cell types and the protein is thought to act as a transcriptional regulator. ' The gene has been shown to have an important role in early embryogenesis,' the control of cell growth, cellular differentiation,3 tissue repair processes,4 and apoptosis. ' 6 Expression of the gene is considered to be a major component in the regulatory processes associated with normal cell proliferation and differentiation. This view is reinforced by the demonstration of gene amplification or an increase in the level of the gene product p62 in a variety of pathological states in which there is perturbation of cell proliferation and differentiation. These include several malignant and premalignant conditions.7 8 The myc gene contains a transcriptional activation domain and a basic helix loop leucine zipper DNA binding and dimerisation domain. Acting as a heterodimer with a structurally related protein, Max, myc can bind DNA in a sequence specific manner, which acts as a transcriptional activator for many genes critical in regulation of cell growth.5 Max is not fully restricted to acting with myc and indeed forms homodimers and heterodimers with Mad and Mxi-1, which then act as antagonists to myc/Max heterodimers, by competing for similar DNA targets. In apoptosis, myc interacts with p53, Bax, and Bcl-x. Myc induced apoptosis appears to occur in cells deprived of certain growth factors or where growth has been arrested by cytotoxic drugs. The role of c-myc role in apoptosis requires binding to Max. 9 Expression of c-myc protein has been shown to be closely associated with the entry of a cell from the Go or resting phase into the cell cycle, while almost complete shut off of c-myc expression accompanies the inhibition of proliferation associated with differentiation.'0 However, this finding is not universal, with other reports suggesting that c-myc protein synthesis is independent of the cell cycle. " Amplification of this oncogene has been observed in several human cancer cell lines (including cervix) and in solid tumour specimens. ' Medium stringency post-hybridisation washings were initially applied using 2x SSC at 600C for 20 minutes, followed by 0.2x SSC for 420C at 20 minutes then O.lx SSC at room temperature for five minutes, and 2x SSC at room temperature for five minutes. Higher stringency washes included 0.2x SSC at 55°C and 600C for 10 minutes, and O.lx SSC at room temperature, 42°C and 55°C.
The hybridisation signal was detected using one step, two step, or three step techniques, as described previously.'8 Colorimetric detection wash achieved using an NBT/BCIP substrate for alkaline phosphatase or aminoethylcarbazole (Zymed kit for peroxidase, California, USA).22 Sections were counterstained with 2% methyl green for alkaline phosphatase detection or haematoxylin for the peroxidase detection system.
Tissue controls for non-isotopic in situ hybridisation (NISH) included HPV positive cervical wart and myocardium (negative for HPV). Reaction controls included hybridisation buffer on its own, biotin/digoxigenin labelled plasmid sequences (pBR322), and irrelevant probe (herpes zoster virus, HZV). Labelled human placental DNA was used to check hybridisation efficiency. For general primer PCR, amplification conditions were similar except 3.5 mM MgCl2 was used and an annealing temperature of 400C was applied.
Type specific HPV PCR products were confirmed by dot blot hybridisation as previously described.23
PCR ANALYSIS OF EXON-1 C-MYC PCR for c-myc was performed using primers designed for fragile sites in exon 1 of the c-myc oncogene which are frequently involved in translocation phenomena and deletions in Table 1 Primer sequences for c-myc exon 1 polymerase chain reaction analysis 
Approximately 100 mg of gel (100 gl equivalent gel volume) was used for each purification. Three volumes of buffer QX1 were added to the gel slice. The mix was incubated at 50°C for 10 minutes. To aid dissolution of the slice, the tube was inverted and gently flicked, every two to three minutes during incubation. One gel volume (100 gl) of isopropanol was added to the mix and the pH of the solution checked using a pH strip. If pH was > 7.5, then 10 jt of 3 M sodium acetate, pH 5.0, were added to the mix and the pH rechecked. (The technique only works when the pH of the solution is < 7.5.) A QIAquick column was placed in a 2 ml collection tube and loaded with the sample and centrifuged at 13 000 rpm for one minute. The flow through was discarded and the QIAquick column was replaced in the same collection tube; 0.5 ml of buffer QIAquick was added to the column and centrifuged at 13,000 rpm for one minute. The column was then washed with 0.75 ml of buffer PE (Qiagen kit) and centrifuged at 13 000 rpm for one minute. The flow-through was discarded and the column was again spun for an additional one minute at 13 000 rpm. The QIAquick column was then placed in a clean 1.5 ml microfuge tube and then 30 p1 of 10 mM Tris-HCl pH 8.8, or HPLC water was added to the centre of the column and centrifuged at 13 000 rpm for one minute. The eluted DNA as then stored at -20°C. For sequencing reactions, 50-100 ng of purified product were taken.
A reaction premix was prepared as follows; 5x sequencing buffer, dNTP mix, A dye terminator, C dye terminator, G dye terminator, T dye terminator, and AmpliTaq DNA polymerase FS (10 units). The amount of terminator added to the pre-mix was adjusted to give an optimal distribution of signal between 10 and 700 bases. If a stronger signal was required at the beginning of the sequencing run, then the amount of terminator was adjusted upwards to 0.6 p1 per reaction.
Positive and negative strand sequencing was performed on selected cases. Cycle sequencing was performed using 3.2 pmol ofthe positive or negative strand primer in the Gene Amp PCR system 9600 (Perkin Elmer) and the following thermocycling profile was adopted: rapid thermal ramp to 96°C, 96°C for 10 seconds, rapid thermal ramp to 50°C, 50°C for five seconds, rapid thermal ramp to 60°C, then 60°C for four minutes. The above thermocycling profile was repeated for 25 cycles. At end of thermocycling, the solution was rapidly cooled to 4°C and held at that temperature. Extension products were then purified as follows:
In a 1.5 ml Eppendorf tube, 2 by the addition of 250 pl of 75% ethanol. The ethanol solution was aspirated off without disturbing the cell pellet. The pellet was then dried in a vacuum centrifuge and resuspended in 5 pl of water.
The ABI PRISM 377 (Perkin Elmer) was used for identification and resolution of sequenced product. A loading buffer containing deionised formamide and 25 mM EDTA pH 8.0, containing 50 mg/ml blue dextran in a ratio of 5:1 formamide to EDTA/blue dextran was prepared.
Samples were then spun in a microfuge and vortexed briefly, after which they were heated to 90°C for two minutes to ensure complete denaturation. The samples were then loaded Samples were run over a 12 hour period and then analysed using sequence navigator software on the ABI PRISM 377 DNA sequencer. Automated sequence comparison for polymorphism analysis was achieved using the ABI sequence navigator and auto-assembled on the ABI PRISM 377 DNA sequencer.
IMMUNOHISTOCHEMICAL DEMONSTRATION OF THE C-MYC ONCOGENE PRODUCT (P62) IN CERVICAL SQUAMOUS CELL CARCINOMAS
Fifty seven squamous cell carcinomas of the cervix were examined for the expression of c-myc protein product p62. In 21 cases, adjacent histologically normal ectocervical mucosa was available for examination, which serves as a control for the immunocytochemical staining (table 3) . Two 5 gm sections were cut onto APES coated slides. Sections were dewaxed in xylene and washed in absolute alcohol. Endogenous peroxidase activity was quenched by incubation in 3% H202 in methanol for 15 minutes. The sections were then rehydrated through graded alcohols to Tris buffered saline (TBS, pH 7.6). Sections were washed for five minutes and were then incubated in 10% normal rabbit serum (NRS) followed by incubation in the mouse monoclonal antibody Mycl-9E10 at a dilution of 1:400. (This antibody is raised against a synthetic peptide of the C-terminus 408-432 of the human c-myc gene product and is a specific and sensitive probe for the protein on immunoblots.25) Following incubation for one hour, sections were washed in TBS and treated again with NRS for 10 minutes. Sections were then incubated with biotin conjugated rabbit antimouse IgG (Dako, Bucks, UK) 1:400 in 10% NRS for 30 minutes. Sections were washed in TBS and then incubated for 30 minutes with Dako AB complex (which is freshly prepared). The sections were finally washed with TBS and the peroxidase reaction was developed by the application of DAB solution (1 mg/ml diaminobenzidine in 50 mM Tris-HCl pH 7.6, containing 10 mM imidazole, activated with 1 jl of 100 vol H202 immediately before use). The reaction was allowed to proceed for two minutes, after which it was stopped by washing in tap water. Sections were counterstained with Mayer's haematoxylin, dehydrated, cleared, and mounted.
Results

HPV PREVALENCE
Of the 40 cases examined for alterations in exon 1 c-myc, 35 were HPV positive (35 HPV 16; one HPV 18) and five negative for any HPV type by general primer HPV PCR. There was no discordance between HPV results with NISH and type specific PCR or general primer HPV PCR (data not shown).
Of the 57 cases examined by immunocytochemistry for p62 localisation, an additional 17 cases were added to the first study cohort . above, including 16 Changes in exon 2 can theoretically result in altered c-myc protein product, whereas changes in the first exon (single base pair changes or small deletions) can result in either c-myc overexpression or higher stability of its messenger RNA.
In this paper, we demonstrate alterations in exon-1 of c-myc in a minority of squamous cell carcinomas of the cervix. Other changes at different sites within exon 1 and 2 of c-myc have been described in COLO 320 cells and Raji cells. The alterations described in this paper are due to small deletions within exon-1, but point polymorphisms occurring within the priming sites could not be excluded in the third case. The findings are concordant with those of Ocadiz et a1 26 and Huang et a121 who have previously described alterations in c-myc in cervical carcinoma. To our knowledge, this is the first report in relation to exon 1, however. Importantly, the alterations uncovered appeared "clonal" as replicate samples showed the same amplicon band pattern. PCR replicative error has been excluded in this experiment (see Methods). In addition, the changes appear tumour specific, as no alterations were found in the adjacent normal cervix in these cases. All cases which showed alterations were HPV positive, although drawing a link between HPV and such alterations is highly speculative. Previously, the integration sites of HPV in relation to c-myc and N-myc have been examined.28 All cases which show exon-1 changes had strong nuclear positivity on p62 immunocytochemistry, suggesting that such alterations may provide an alternative route to c-myc activation in early squamous cell carcinoma.
Secondly, we have examined the immunohistochemical localisation of c-myc protein product p62 using the monoclonal antibody Mycl-9E10. Increased expression of the cellular oncogene c-myc has been described in a variety of human tumours. The gene encodes a polypeptide with predicated molecular weight of 49 kDa, but which shows aberrant electrophoretic mobility on polyacrylamide gel electrophoresis to give an apparent molecular weight of around 62 kDa (p62 c-myc). Biochemical and immunofluoresence studies of cell lines in vitro have indicated that the protein is normally located in the cell nucleus. Its biological half life is approximately 15 to 20 minutes. Although p62 c-myc in vitro binds non-specifically to DNA, in vivo the greater proportion of the protein appears to remain unbound, having a rather weak association with the nuclear matrix.25 During mitosis, p62 becomes dispersed throughout the cytoplasm, having no association with the condensed chromosomes. Apart from this situation, very little p62 is normally found in cytoplasm.
The monoclonal antibody Mycl-9E10 used in this study was raised against a synthetic peptide of residues 408-432 of p62 c-myc and has been shown by its originators to recognise an epitope of the human c-myc protein p62.25 It has been proved to be sensitive in immunoblotting experiments. However, immunohistochemical studies with monoclonal Mycl-9E10 and its closely related Mycl-6E10 have produced conflicting results when used with formalin fixed tissues. Mycl-6E10 appears to recognise a protein present in both the nucleus and the cytoplasm. Suggestions for this unexpected distribution of p62 have included poor tissue fixation condition or extraction of p62 by salt or low temperatures. Alternatively, it is possible that this antibody may cross react with an unrelated antigen in the cell. 29 In this study, the cellular localisation of c-myc protein was examined in 57 cases of squamous cell carcinoma of the cervix (including the cases examined for exon-1 alterations). The predominant staining pattern was cytoplasmic in 44 cases (table 3, fig 3) . Equal nuclear and cellular staining was seen in nine cases, which consisted of areas of exclusively nuclear and cytoplasmic staining, both of which were present in different areas of the section, neither pattern accounting for 90% or more of the staining pattern. Greater nuclear than cellular staining was seen in four cases. To serve as an internal control, the normal cervical margin in some of the excised squamous carcinomas (where available) was used to assess the predominant staining pattern in these regions. The pattern of results in the normal cervical margin reflects those in normal tissues, where there is a definite correlation between p62 nuclear localisation and normally proliferating cells. Interestingly, Hughes et al 9 showed higher c-myc positivity in normal epithelium (63%) than in specimens with cervical intraepithelial neoplasia grades 2 or 3 (20%) or invasive carcinoma (0%), as assessed by flow cytometry. The finding of p62 localisation in normal relative to dysplastic epithelium may be a reflection of increased turnover of protein in dysplastic cells. Pulacarz et al'0 have previously shown pancellular c-myc expression in endocervical mucosa in 90% of glandular intraepithelial neoplasia and in 100% of adenocarcinomas.
The results of our study again emphasise that fixation procedures in immunolocalisation of the c-myc product must be taken into account when analysing results. There appears to be a shift from the normal nuclear localisation of p62 to the cytoplasmic compartment in the malignant squamous ectocervical cell. The precise nuclear association of p62 in carcinomas may be more labile because of pH changes within the malignant cell, ATP concentration, or release of proteolyic enzymes or other undefined cellular/nuclear factors. One possible explanation for this cytoplasmic shift phenomenon may be a biologically significant difference representing accumulation of newly synthesised p62 in the cytoplasm of these malignant cells, or a relative or absolute deficiency of an undefined nuclear transport mechanism for p62. In addition, the newly formed protein may be unable to bind in the nucleus or its degradation or inactivation may be accentuated.
CONCLUSIONS
In summary, we have shown alterations in exon 1 of c-myc in a minority of cervical cancers, and increased expression of p62 in a cohort of HPV positive and negative cervical squamous cell carcinomas. Alterations in exon 1 may provide the malignant cell with an additional route to activation/stabilisation of c-myc, independent of amplification. Larger studies are now under way to determine the precise prevalence of such alterations and whether similar phenomena occur in exon 2.
